Disentangling the relationship between tumor genetic programs and immune responsiveness

Current Opinion in Immunology

Volumn 39, Issue , 2016, Pages 150-158

  Bedognetti, Davide ^a   Hendrickx, Wouter ^a   Ceccarelli, Michele ^b   Miller, Lance D ^c   Seliger, Barbara ^d  

^a SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

^b QATAR COMPUTING RESEARCH INSTITUTE   (Qatar)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE;

ACTIVE IMMUNIZATION; ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; CANCER CELL; CANCER GENETICS; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CARCINOGENESIS; COPY NUMBER VARIATION; CORRELATION ANALYSIS; DRUG TARGETING; GENE MUTATION; GENOME ANALYSIS; HUMAN; HUMAN GENOME; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOREGULATION; MELANOMA; NONHUMAN; OVARY CANCER; PHENOTYPE; QUANTITATIVE GENETICS; REVIEW; TH1 CELL; TREATMENT RESPONSE; TUMOR IMMUNITY; TUMOR IMMUNOLOGY; UTERINE CERVIX CANCER; ANIMAL; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; TUMOR MICROENVIRONMENT;

ANIMALS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; TH1 CELLS; TUMOR MICROENVIRONMENT;

EID: 84960093795     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2016.02.001     Document Type: Review

References (76)

1. Galon J., Angell Helen K., Bedognetti D., Marincola Francesco M. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 2013, 39:11-26.
2. Wang E., Bedognetti D., Marincola F.M. Prediction of response to anticancer immunotherapy using gene signatures. J Clin Oncol 2013, 31:2369-2371.
3. Bindea G., Mlecnik B., Angell H.K., Galon J. The immune landscape of human tumors: implications for cancer immunotherapy. Oncoimmunology 2014, 3:e27456.
4. Panelli M.C., Stashower M.E., Slade H.B., Smith K., Norwood C., Abati A., Fetsch P., Filie A., Walters S.A., Astry C., et al. Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection. Genome Biol 2007, 8:R8.
5. Wang E., Miller L.D., Ohnmacht G.A., Mocellin S., Perez-Diez A., Petersen D., Zhao Y., Simon R., Powell J.I., Asaki E., et al. Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res 2002, 62:3581-3586.
6. Weiss G.R., Grosh W.W., Chianese-Bullock K.A., Zhao Y., Liu H., Slingluff C.L., Marincola F.M., Wang E. Molecular insights on the peripheral and intratumoral effects of systemic high-dose rIL-2 (aldesleukin) administration for the treatment of metastatic melanoma. Clin Cancer Res 2011, 17:7440-7450.
7. Bedognetti D., Wang E., Sertoli M.R., Marincola F.M. Gene-expression profiling in vaccine therapy and immunotherapy for cancer. Expert Rev Vaccines 2010, 9:555-565.
8. Ulloa-Montoya F., Louahed J., Dizier B., Gruselle O., Spiessens B., Lehmann F.F., Suciu S., Kruit W.H., Eggermont A.M., Vansteenkiste J., et al. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J Clin Oncol 2013, 31:2388-2395.
9. Ji R.R., Chasalow S.D., Wang L., Hamid O., Schmidt H., Cogswell J., Alaparthy S., Berman D., Jure-Kunkel M., Siemers N.O., et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 2012, 61:1019-1031.
10. Herbst R.S., Soria J.C., Kowanetz M., Fine G.D., Hamid O., Gordon M.S., Sosman J.A., McDermott D.F., Powderly J.D., Gettinger S.N., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014, 515:563-567.
11. Ribas A., Robert C., Hodi F.S., Wolchok J., Joshua A.M., Hwu W.J., Weber J., Zarour H., Kefford R., Kang S.P., et al. Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. J Clin Oncol 2015, 33.
12. Spivey T.L., Uccellini L., Ascierto M.L., Zoppoli G., De Giorgi V., Delogu L.G., Engle A.M., Thomas J.M., Wang E., Marincola F.M., Bedognetti D. Gene expression profiling in acute allograft rejection: challenging the immunologic constant of rejection hypothesis. J Transl Med 2011, 9:174. 10.1186/1479-5876-9-174.
13. Wang E., Worschech A., Marincola F.M. The immunologic constant of rejection. Trends Immunol 2008, 29:256-262.
14. Denkert C., von Minckwitz G., Brase J.C., Sinn B.V., Gade S., Kronenwett R., Pfitzner B.M., Salat C., Loi S., Schmitt W.D., et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol 2015, 33:983-991.
15. Stoll G., Enot D., Mlecnik B., Galon J., Zitvogel L., Kroemer G. Immune-related gene signatures predict the outcome of neoadjuvant chemotherapy. Oncoimmunology 2014, 3:e27884.
16. Perez E.A., Thompson E.A., Ballman K.V., Anderson S.K., Asmann Y.W., Kalari K.R., Eckel-Passow J.E., Dueck A.C., Tenner K.S., Jen J., et al. Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial. J Clin Oncol 2015, 33:701-708.
17. Bedognetti D., Hendrickx W., Marincola F.M., Miller L.D. Prognostic and predictive immune gene signatures in breast cancer. Curr Opin Oncol 2015, 27:433-444.
18. Taube J.M., Klein A., Brahmer J.R., Xu H., Pan X., Kim J.H., Chen L., Pardoll D.M., Topalian S.L., Anders R.A. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014, 20:5064-5074.
19. Perez-Chanona E., Trinchieri G. The role of microbiota in cancer therapy. Curr Opin Immunol 2016, 39:75-81. [in this issue]. 10.1016/j.coi.2016.01.003.
20. Vetizou M., Pitt J.M., Daillere R., Lepage P., Waldschmitt N., Flament C., Rusakiewicz S., Routy B., Roberti M.P., Duong C.P., et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 2015, 350:1079-1084.
21. Ugurel S., Schrama D., Keller G., Schadendorf D., Brocker E.B., Houben R., Zapatka M., Fink W., Kaufman H.L., Becker J.C. Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy. Cancer Immunol Immunother 2008, 57:685-691.
22. Bedognetti D., Spivey T.L., Zhao Y., Uccellini L., Tomei S., Dudley M.E., Ascierto M.L., De Giorgi V., Liu Q., Delogu L.G., et al. CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2. Br J Cancer 2013, 109:2412-2423.
23. Uccellini L., De Giorgi V., Zhao Y., Tumaini B., Erdenebileg N., Dudley M.E., Tomei S., Bedognetti D., Ascierto M.L., Liu Q., et al. IRF5 gene polymorphisms in melanoma. J Transl Med 2012, 10:170.
24. Wang E., Zhao Y., Monaco A., Uccellini L., Kirkwood J.M., Spyropoulou-Vlachou M., Panelli M.C., Marincola F.M., Gogas H. A multi-factorial genetic model for prognostic assessment of high risk melanoma patients receiving adjuvant interferon. PLoS One 2012, 7:e40805.
25. Breunis W.B., Tarazona-Santos E., Chen R., Kiley M., Rosenberg S.A., Chanock S.J. Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade. J Immunother 2008, 31:586-590.
26. Queirolo P., Morabito A., Laurent S., Lastraioli S., Piccioli P., Ascierto P.A., Gentilcore G., Serra M., Marasco A., Tornari E., et al. Association of CTLA-4 polymorphisms with improved overall survival in melanoma patients treated with CTLA-4 blockade: a pilot study. Cancer Invest 2013, 31:336-345.
27. Hamid O., Chasalow S.D., Tsuchihashi Z., Alaparthy S., Galbraith S., Berman D. Association of baseline and on-study tumor biopsy markers with clinical activity in patients (pts) with advanced melanoma treated with ipilimumab. J Clin Oncol 2009, 27.
28. Gogas H., Dafni U., Koon H., Spyropoulou-Vlachou M., Metaxas Y., Buchbinder E., Pectasides E., Tsoutsos D., Polyzos A., Stratigos A., et al. Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial. J Transl Med 2010, 8:108.
29. Bedognetti D., Tomei S., W.H F.M., M, E.W Toward the identification of genetic determinants of responsiveness to cancer immunotherapy. Developments in T Cell Based Cancer Immunotherapies 2015, Elsevier. P.A. E Wang, D. Stroncek (Eds.).
30. Seliger B. The link between MHC class I abnormalities of tumors, oncogenes, tumor suppressor genes, and transcription factors. J Immunotoxicol 2014, 11:308-310.
31. Pavlova N.N., Thompson C.B. The emerging hallmarks of cancer metabolism. Cell Metab 2016, 23:27-47.
32. Miranda-Goncalves V., Reis R.M., Baltazar F. Lactate transporters and pH regulation: potential therapeutic targets in glioblastomas. Curr Cancer Drug Targets 2015.
33. Munn D.H., Bronte V. Immune suppressive mechanisms in the tumor microenvironment. Curr Opin Immunol 2015, 39:1-6.
34. Chiarugi P., Cirri P. Metabolic exchanges within tumor microenvironment. Cancer Lett 2015.
35. Rajani K.R., Vile R.G. Harnessing the power of onco-immunotherapy with checkpoint inhibitors. Viruses 2015, 7:5889-5901.
36. Atkins D., Breuckmann A., Schmahl G.E., Binner P., Ferrone S., Krummenauer F., Storkel S., Seliger B. MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma. Int J Cancer 2004, 109:265-273.
37. Qin Z., Harders C., Cao X., Huber C., Blankenstein T., Seliger B. Increased tumorigenicity, but unchanged immunogenicity, of transporter for antigen presentation 1-deficient tumors. Cancer Res 2002, 62:2856-2860.
38. Griffioen M., Steegenga W.T., Ouwerkerk I.J., Peltenburg L.T., Jochemsen A.G., Schrier P.I. Repression of the minimal HLA-B promoter by c-myc and p53 occurs through independent mechanisms. Mol Immunol 1998, 35:829-835.
39. Tudor C.S., Dawson C.W., Eckhardt J., Niedobitek G., Buttner A.C., Seliger B., Hartmann A., Buettner M. c-Myc and EBV-LMP1: two opposing regulators of the HLA class I antigen presentation machinery in epithelial cells. Br J Cancer 2012, 106:1980-1988.
40. Smith C., Santi M., Rajan B., Rushing E.J., Choi M.R., Rood B.R., Cornelison R., MacDonald T.J., Vukmanovic S. A novel role of HLA class I in the pathology of medulloblastoma. J Transl Med 2009, 7:59.
41. Sers C., Kuner R., Falk C.S., Lund P., Sueltmann H., Braun M., Buness A., Ruschhaupt M., Conrad J., Mang-Fatehi S., et al. Down-regulation of HLA Class I and NKG2D ligands through a concerted action of MAPK and DNA methyltransferases in colorectal cancer cells. Int J Cancer 2009, 125:1626-1639.
42. El-Jawhari J.J., El-Sherbiny Y.M., Scott G.B., Morgan R.S., Prestwich R., Bowles P.A., Blair G.E., Tanaka T., Rabbitts T.H., Meade J.L., et al. Blocking oncogenic RAS enhances tumour cell surface MHC class I expression but does not alter susceptibility to cytotoxic lymphocytes. Mol Immunol 2014, 58:160-168.
43. Bukur J., Herrmann F., Handke D., Recktenwald C., Seliger B. Identification of E2F1 as an important transcription factor for the regulation of tapasin expression. J Biol Chem 2010, 285:30419-30426.
44. Steven A., Leisz S., Massa C., Iezzi M., Lattanzio R., Lamolinara A., Bukur J., Muller A., Hiebl B., Holzhausen H.J., et al. HER-2/neu mediates oncogenic transformation via altered CREB expression and function. Mol Cancer Res 2013, 11:1462-1477.
45. Neerincx A., Jakobshagen K., Utermohlen O., Buning H., Steimle V., Kufer T.A. The N-terminal domain of NLRC5 confers transcriptional activity for MHC class I and II gene expression. J Immunol 2014, 193:3090-3100.
46. Lorenzi S., Forloni M., Cifaldi L., Antonucci C., Citti A., Boldrini R., Pezzullo M., Castellano A., Russo V., van der Bruggen P., et al. IRF1 and NF-kB restore MHC class I-restricted tumor antigen processing and presentation to cytotoxic T cells in aggressive neuroblastoma. PLoS One 2012, 7:e46928.
47. Zheng P., Guo Y., Niu Q., Levy D.E., Dyck J.A., Lu S., Sheiman L.A., Liu Y. Proto-oncogene PML controls genes devoted to MHC class I antigen presentation. Nature 1998, 396:373-376.
48. Xia M., Zhang J.Q., Shen Y.Q., Xu L.H., Chen A.Q., Miao F.Q., Xie W. Concordant expression of proto-oncogene promyelocytic leukemia and major histocompatibility antigen HLA class I in human hepatocellular carcinoma. Tissue Antigens 2007, 70:272-282.
49. Respa A., Bukur J., Ferrone S., Pawelec G., Zhao Y., Wang E., Marincola F.M., Seliger B. Association of IFN-gamma signal transduction defects with impaired HLA class I antigen processing in melanoma cell lines. Clin Cancer Res 2011, 17:2668-2678.
50. Ramana C.V., Grammatikakis N., Chernov M., Nguyen H., Goh K.C., Williams B.R., Stark G.R. Regulation of c-myc expression by IFN-gamma through Stat1-dependent and -independent pathways. EMBO J 2000, 19:263-272.
51. Schlee M., Holzel M., Bernard S., Mailhammer R., Schuhmacher M., Reschke J., Eick D., Marinkovic D., Wirth T., Rosenwald A., et al. C-myc activation impairs the NF-kappaB and the interferon response: implications for the pathogenesis of Burkitt's lymphoma. Int J Cancer 2007, 120:1387-1395.
52. Herrmann F., Lehr H.A., Drexler I., Sutter G., Hengstler J., Wollscheid U., Seliger B. HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathway. Cancer Res 2004, 64:215-220.
53. Akbay E.A., Koyama S., Carretero J., Altabef A., Tchaicha J.H., Christensen C.L., Mikse O.R., Cherniack A.D., Beauchamp E.M., Pugh T.J., et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 2013, 3:1355-1363.
54. Lastwika K.J., Wilson W., III, Li Q.K., Norris J., Xu H., Ghazarian S.R., Kitagawa H., Kawabata S., Taube J.M., Yao S., et al. Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer. Cancer Res 2016, 76:227-238.
55. Mimura K., Ando T., Poschke I., Mougiakakos D., Johansson C.C., Ichikawa J., Okita R., Nishimura M.I., Handke D., Krug N., et al. T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2. Int J Cancer 2011, 128:390-401.
56. Angell T.E., Lechner M.G., Jang J.K., LoPresti J.S., Epstein A.L. MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro. Clin Cancer Res 2014, 20:6034-6044.
57. Mimura K., Shiraishi K., Mueller A., Izawa S., Kua L.F., So J., Yong W.P., Fujii H., Seliger B., Kiessling R., et al. The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer. J Immunol 2013, 191:6261-6272.
58. Spivey T.L., De Giorgi V., Zhao Y., Bedognetti D., Pos Z., Liu Q., Tomei S., Ascierto M.L., Uccellini L., Reinboth J., et al. The stable traits of melanoma genetics: an alternate approach to target discovery. BMC Genomics 2012, 13:156.
59. Spranger S., Bao R., Gajewski T.F. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature 2015, 523:231-235.
60. Tomei S., Bedognetti D., De Giorgi V., Sommariva M., Civini S., Reinboth J., Al Hashmi M., Ascierto M.L., Liu Q., Ayotte B.D., et al. The immune-related role of BRAF in melanoma. Mol Oncol 2015, 9:93-104.
61. Hu-Lieskovan S., Mok S., Homet Moreno B., Tsoi J., Robert L., Goedert L., Pinheiro E.M., Koya R.C., Graeber T.G., Comin-Anduix B., et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med 2015, 7. 279ra241.
62. Simeone I, Hendricks W, Miller L, Bensmail H, Marincola F, Wang E, Ceccarelli M, Bedognetti D: Toward the identification of genetic determinants of breast cancer immune responsiveness. Breast Cancer Immunotherapy Symposium (BRECIS): Sidra Symposia Series; April 13-14, Doha, Qatar; J Immunother Cancer 2015, 3(Suppl 1):1. doi:10.1186/2051-1426-3-S1-P1.
63. Loi S., Dushyanthen S., Beavis P.A., Salgado R., Denkert C., Savas P., Combs S., Rimm D.L., Giltnane J.M., Estrada M.V., et al. RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors. Clin Cancer Res 2015.
64. Mlecnik B., Bindea G., Angell H.K., Sasso M.S., Obenauf A.C., Fredriksen T., Lafontaine L., Bilocq A.M., Kirilovsky A., Tosolini M., et al. Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. Sci Transl Med 2014, 6. 228ra237.
65. Bindea G., Mlecnik B., Tosolini M., Kirilovsky A., Waldner M., Obenauf A.C., Angell H., Fredriksen T., Lafontaine L., Berger A., et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013, 39:782-795.
66. Linsley P.S., Speake C., Whalen E., Chaussabel D. Copy number loss of the interferon gene cluster in melanomas is linked to reduced T cell infiltrate and poor patient prognosis. PLoS One 2014, 9:e109760.
67. Liu Q., Tomei S., Ascierto M.L., De Giorgi V., Bedognetti D., Dai C., Uccellini L., Spivey T., Pos Z., Thomas J., et al. Melanoma NOS1 expression promotes dysfunctional IFN signaling. J Clin Invest 2014, 124:2147-2159.
68. Peng W., Chen J.Q., Liu C., Malu S., Creasy C., Tetzlaff M.T., Xu C., McKenzie J.A., Zhang C., Liang X., et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov 2015.
69. Rutledge W.C., Kong J., Gao J., Gutman D.A., Cooper L.A., Appin C., Park Y., Scarpace L., Mikkelsen T., Cohen M.L., et al. Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class. Clin Cancer Res 2013, 19:4951-4960.
70. Mittendorf E.A., Philips A.V., Meric-Bernstam F., Qiao N., Wu Y., Harrington S., Su X., Wang Y., Gonzalez-Angulo A.M., Akcakanat A., et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res 2014, 2:361-370.
71. Rooney M.S., Shukla S.A., Wu C.J., Getz G., Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 2015, 160:48-61.
72. Hoadley K.A., Yau C., Wolf D.M., Cherniack A.D., Tamborero D., Ng S., Leiserson M.D., Niu B., McLellan M.D., Uzunangelov V., et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 2014, 158:929-944.
73. Quigley D., Silwal-Pandit L., Dannenfelser R., Langerod A., Vollan H.K., Vaske C., Siegel J.U., Troyanskaya O., Chin S.F., Caldas C., et al. Lymphocyte invasion in IC10/basal-like breast tumors is associated with wild-type TP53. Mol Cancer Res 2015, 13:493-501.
74. Rizvi N.A., Hellmann M.D., Snyder A., Kvistborg P., Makarov V., Havel J.J., Lee W., Yuan J., Wong P., Ho T.S., et al. Cancer immunology, mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015, 348:124-128.
75. Snyder A., Makarov V., Merghoub T., Yuan J., Zaretsky J.M., Desrichard A., Walsh L.A., Postow M.A., Wong P., Ho T.S., et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014, 371:2189-2199.
76. Le D.T., Uram J.N., Wang H., Bartlett B.R., Kemberling H., Eyring A.D., Skora A.D., Luber B.S., Azad N.S., Laheru D., et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015, 372:2509-2520.